Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

D-Wave Quantum Shares Face Insider Selling Pressure

Robert Sasse by Robert Sasse
November 23, 2025
in AI & Quantum Computing, Insider Trading, Tech & Software
0
D-Wave Quantum Stock
0
SHARES
76
VIEWS
Share on FacebookShare on Twitter

The quantum computing sector is generating headlines this week, though not for the reasons investors might hope. D-Wave Quantum finds itself in the spotlight after a surprising move by one of its top executives raised questions about the company’s valuation prospects. Despite delivering an extraordinary 175% year-to-date rally, the company’s Chief Financial Officer has decided to cash in a substantial portion of his holdings.

CFO Executes Major Stock Sale

John M. Markovich, D-Wave Quantum’s CFO, has triggered concern among shareholders by divesting 200,000 shares at an average price of $22.94. This transaction, reported Sunday, netted the financial chief approximately $4.59 million while reducing his stake by nearly 12%. Although Markovich maintains a significant position of about 1.48 million shares, the timing of this disposal has market participants questioning whether insiders believe the stock has reached its peak.

Spectacular Gains Meet Extreme Valuation

Trading recently concluded at $20.41 per share, reflecting minor daily losses. However, the broader picture reveals a more dramatic story. While the 175% annual advance appears impressive, the stock has retreated substantially from its yearly highs that once showed gains exceeding 400%.

The company’s valuation metrics continue to paint a challenging picture. With a market capitalization hovering around $7.1 billion and a price-to-sales ratio surpassing 200, the current share price appears to incorporate substantial future growth expectations. This environment creates turbulent trading conditions where any news can trigger significant price movements.

Should investors sell immediately? Or is it worth buying D-Wave Quantum?

Institutional Support Contrasts with Insider Action

Despite the CFO’s selling activity, institutional investors demonstrate continued confidence in D-Wave Quantum’s prospects. Recent regulatory filings reveal substantial buying from major financial players:

  • The Police & Firemen’s Retirement System of New Jersey boosted its holdings by a notable 66.5%
  • Investment giants including Vanguard and UBS expanded their positions during the third quarter
  • Institutional ownership now represents approximately 42.47% of outstanding shares

Financial Health Shows Mixed Signals

Operational developments present a more nuanced backdrop against which to evaluate the insider selling activity. The company recently strengthened its balance sheet through warrant exercises that injected $54.6 million in fresh capital. This liquidity enhancement provides crucial resources to support D-Wave’s commercialization initiatives.

Third-quarter financial results offered some positive surprises:

  • Revenue reached $3.7 million, exceeding analyst projections of $3.03 million
  • Earnings per share came in at -$0.05, better than the anticipated -$0.07 loss
  • Analyst price targets remain optimistic, with Canaccord Genuity maintaining $41.00 and Benchmark at $35.00

Investors now face a complex decision-making environment. Bullish analyst commentary and improved liquidity compete against stretched valuations and insider selling activity. The shares continue to represent a highly speculative investment that depends heavily on successful execution of the company’s long-term strategy.

Ad

D-Wave Quantum Stock: Buy or Sell?! New D-Wave Quantum Analysis from February 7 delivers the answer:

The latest D-Wave Quantum figures speak for themselves: Urgent action needed for D-Wave Quantum investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

D-Wave Quantum: Buy or sell? Read more here...

Tags: D-Wave Quantum
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Quantum eMotion Stock
AI & Quantum Computing

Quantum eMotion Advances Toward US Exchange Listing

February 6, 2026
Next Post
Metaplanet Stock

Metaplanet's Bold Bitcoin Bet: A $135 Million Gamble Amid Market Turbulence

DroneShield Stock

DroneShield Stock Plummets Amid Leadership Crisis

Coca-Cola Stock

Coca-Cola Shares Surge as Major Investor Boosts Stake

Recommended

CRWD stock news

Tower Research Capital LLC TRC Demonstrates Unwavering Confidence in CrowdStrike Holdings as Cybersecurity Leader

2 years ago
Efficiently Reporting an Absence on WalmartOne: A Step-by-Step Guide for Employees

Beacon Announces Interim Chief Financial Officer

2 years ago

Alaska Airlines Boeing 737 Investigation Missing Bolts and Safety Measures

2 years ago

Impressive Financial Performance for Kiniksa Pharmaceuticals

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Trending

Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

by Rodolfo Hanigan
February 7, 2026
0

Universal Insurance Holdings has reaffirmed its commitment to shareholder returns, declaring its regular quarterly dividend despite a...

Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds
  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com